Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Hepatology. 2022 Jan 23;76(3):630–645. doi: 10.1002/hep.32266

Fig. 7. Disruption of type I interferon signaling abrogates the synergistic effect of polyIC and αPD-L1 in the liver.

Fig. 7.

A). The scheme of Combo treatment with or without antibody to type I interferon receptor (αIFNαR1).

B). Representative macroscopic view and H&E staining of liver sections with samples collected on day 17.

C-D). The liver weights (C) and liver to body (L/B) weight ratios (D), n = 5. Statistical analysis: unpaired t-test with Welch’s correction or Mann-Whitney test, compared with Ctrl.

E). The survival curves of mice, n = 5–6. Log-Rank (Mantel-Cox) test compared with Ctrl.

F). The macroscopic view of livers and H&E staining of liver sections. WT: the C57BL/6J mice; Ifnar1−: type I interferon receptor knockout mice.

G). The survival curves of mice, n = 7–8. Log-Rank (Mantel-Cox) test.